within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AX04_Dacarbazine;

model Dacarbazine
  extends Pharmacolibrary.Drugs.ATC.L.L01AX04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01AX04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dacarbazine is an antineoplastic agent classified as an alkylating agent, primarily used for the treatment of melanoma and Hodgkin's lymphoma. It interferes with DNA replication and transcription, leading to cell death. It is approved and used today mainly in chemotherapy protocols for these malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult cancer patients, both sexes, typical age range for chemotherapy protocols.</p><h4>References</h4><ol><li><p>Gao, L, et al., &amp; Kong, R (2023). Pharmacokinetics of Dacarbazine and Unesbulin and CYP1A2-Mediated Drug Interactions in Patients With Leiomyosarcoma. <i>Clinical and translational science</i> 17(2) –. DOI:<a href=\"https://doi.org/10.1111/cts.13709\">10.1111/cts.13709</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38129988/\">https://pubmed.ncbi.nlm.nih.gov/38129988</a></p></li><li><p>Kantrowitz-Gordon, I, et al., &amp; Hebert, MF (2018). Pharmacokinetics of dacarbazine (DTIC) in pregnancy. <i>Cancer chemotherapy and pharmacology</i> 81(3) 455–460. DOI:<a href=\"https://doi.org/10.1007/s00280-017-3511-6\">10.1007/s00280-017-3511-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29305638/\">https://pubmed.ncbi.nlm.nih.gov/29305638</a></p></li><li><p>Kalsi, GS, et al., &amp; Rootman, J (1991). Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit. <i>Canadian journal of ophthalmology. Journal canadien d&#x27;ophtalmologie</i> 26(5) 247–251. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1933662/\">https://pubmed.ncbi.nlm.nih.gov/1933662</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dacarbazine;
